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Background: It is well known that cytomegalovirus esophagitis occurs in immunosuppressed patients. However, few
reports have described cytomegalovirus esophagitis occurring during chemoradiotherapy for esophageal cancer.
Case presentation: We report two cases of patients with cytomegalovirus esophagitis that developed during
chemoradiotherapy for esophageal cancer. Cytomegalovirus esophagitis was diagnosed based on the presence of
intranuclear inclusions in tumor biopsy specimens. The two Japanese patients presented with anorexia and fever, which
improved with anti-cytomegalovirus treatment, and intranuclear inclusions were no longer seen in the specimens.
Conclusions: The possibility of cytomegalovirus esophagitis must be kept in mind for patients with esophageal cancer
presenting with prolonged fever or digestive symptoms while receiving chemoradiotherapy.
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Cytomegalovirus (CMV) usually remains latent, but reacti-
vation of the virus can occur in immunocompromised pa-
tients who have undergone bone marrow transplantation,
have human immunodeficiency virus (HIV) infection, or
are receiving immunosuppressant agents [1]. Under these
circumstances, active infection may occur in many organs,
particularly in the gastrointestinal tract (GIT), including the
esophagus and colon [2, 3]. Patients with CMV infection of
the GIT may manifest symptoms such as nausea, vomiting,
chest pain, dysphagia, anorexia, and fever.
Diagnosis of CMV infection is made by endoscopic bi-
opsy [4]. Detection of CMV antigenemia may support the
diagnosis, but testing is not sufficiently sensitive and may
yield false-negative results. While CMV infection is not rare
in patients with HIV infection or those who have received
stem cell transplantation, few reports have described cases
of CMV esophagitis developing during chemoradiotherapy
for esophageal cancer. We report herein two cases of* Correspondence: k.umemoto.k@gmail.com
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chemoradiotherapy for esophageal cancer in Japan.Case presentation
The clinical characteristics of the two Japanese patients
are summarized in Tables 1 and 2.Case 1
A 77-year-old Japanese man with stage IIIC esophageal
cancer was admitted to the hospital with fever (grade 1,
Common Terminology Criteria for Adverse Events
[CTCAE], version 4.0) and nausea (grade 2) after a second
course of 5-fluorouracil (5-FU) (700 mg/m2/day, days 1–5
every 4 weeks) with concurrent radiotherapy (59.4 Gy/33
fr). His symptoms had shown no response to antibiotics
or antifungal drugs. Nadir white blood cell (WBC) and
lymphocyte counts before antiviral drug treatment were
820/μL (grade 4) and 180/μL (grade 4). CMV esophagitis
was diagnosed based on the finding of intranuclear inclu-
sions and positive CMV antibody immunostaining in a
tumor biopsy, as well as a positive test result for CMV
antigenemia. Findings on endoscopy at diagnosis are
shown in Fig. 1 and pathological findings are provided inle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Patient characteristics


















Abbreviations: M Male, IIIC UICC 7th stageIIIC, 5-FU 5-fluorouracil, FP 5-FU
+ cisplatin
Fig. 1 Upper gastrointestinal endoscopic findings in case 1. An ulcer
with a white base is seen in the esophagus
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and then valganciclovir (VGCV) (450 mg every 2 days;
reduced dose due to renal dysfunction) resulted in reso-
lution of his fever and amelioration of his nausea (Fig. 3).
Intranuclear inclusions were no longer detected in biopsy
specimens from the tumor after treatment, and the test
for CMV antigenemia also yielded negative results on day
43 after the completion of treatment.
Case 2
A 61-year-old Japanese man with stage IIIC esophageal
cancer presented with anorexia (grade 2) and fever
(grade 1) after two courses of treatment with 5-FU (700
mg/m2/day, days 1–5 every 4 weeks) and cisplatin (70
mg/m2/day, day 1 every 4 weeks) with concurrent radio-
therapy (60 Gy/30 fr). A lesion biopsy obtained after two
courses of treatment revealed findings consistent with
CMV esophagitis and serological testing for CMV antigene-
mia also yielded positive results. Nadir WBC and lympho-
cyte counts before antiviral pharmacotherapy were 2200/μL
(grade 1) and 391/μL (grade 3). Treatment with VGCV
(900 mg/day) followed by GCV (5 mg/kg/day) resulted in
amelioration of his anorexia and fever. In addition, intra-
nuclear inclusions and positive CMV antibody immuno-
staining were no longer evident in a lesion biopsy obtained
after treatment, and test results for CMV antigenemia also
became negative on day 128 after completion of antiviral
treatment.
Discussion
CMV esophagitis is a rare complication of
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Clinical features at diagnosis of CMV esophagitis and after treatment with antiviral
intranuclear inclusions disappeared, and the test for CMV antigenemia also became
Abbreviations: CMV cytomegalovirus, WBC white blood cell, CRP C-reactive protein, G
aThe nadir WBC and lymphocyte counts before the diagnosis of CMV infection
bSerum CRP was measured at diagnosis of CMV esophagitismost commonly observed in patients who have under-
gone stem cell transplantation. Few reports in the litera-
ture appear to have described CMV infection of the GIT
developing during chemoradiotherapy in patients with
solid tumors [5].
In the cases reported here, CMV esophagitis was diag-
nosed based on examination of biopsy specimens ob-
tained to evaluate the efficacy of anticancer regimens. In
both Japanese cases, CMV esophagitis developed after
two courses of chemotherapy (51–58 days after initiating
treatment), and biopsy specimens were obtained from
the site of the tumors, which were visualized endoscop-
ically as ulcers with a white base. Test results for CMV
antigenemia became negative after treatment with anti-
viral drugs in both cases. These patients manifested
nausea or fever, and both symptoms and endoscopic
findings improved with treatment. The present results
suggest the utility of starting antiviral treatment for
CMV esophagitis as soon as the diagnosis is estab-














drugs. Low lymphocyte counts at diagnosis of CMV esophagitis are shown. The
negative after the treatment
CV ganciclovir, VGCV valganciclovir
Fig. 2 The arrow shows pathological findings of intranuclear inclusions obtained with biopsy at esophagus ulcer. There is the enlarged figure of
the intranuclear inclusion on lower right box which suggest active esophagitis of CMV
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findings is difficult. The appearance of lesions is nonspe-
cific, including ulcers and erosions in our cases, al-
though a past report described specific features of CMV,
such as irregular map-like erosions separate from tumor
lesions [5]. CMV infection is confirmed mainly by im-
munostaining of tissue specimens obtained from the site
of infection, and we recommend taking a lesion biopsy
and indicating clinical suspicion of CMV infection to the
pathologist, to ensure additional processing of the speci-
mens, particularly for patients presenting with fever or
digestive symptoms. A positive test result for CMV anti-
genemia may also support the diagnosis of CMV esopha-
gitis by permitting rapid detection of CMV proteins in
peripheral blood leukocytes, but the positivity rate at on-
set of CMV gastroenteritis is reported as only 50 % [6].Fig. 3 Clinical course from day 31 (after second course of FP) in
case 1. Abbreviations: MEPM meropenem, VCM vancomycin, MCFG
micafangin, PIPC/TAZ piperacillin/tazobactam, GCV ganciclovir, VGCV
valganciclovir, FP 5-FU + cisplatinCMV infection in patients with esophageal cancer may
be underreported, because fever and gastrointestinal
symptoms in such patients may not be attributed to CMV
infection, and instead simply managed as symptoms of
radiation esophagitis or side effects of chemoradiotherapy.
Severe lymphocytopenia as well as low WBC counts and
neutropenia may lead to CMV esophagitis during chemo-
radiotherapy [7, 8].Conclusions
We have reported two rare cases of patients with CMV
esophagitis that developed during chemoradiotherapy
for esophageal cancer. Physicians and pathologists
should keep the possibility of CMV esophagitis in mind
for patients with esophageal cancer presenting with pro-
longed fever or digestive symptoms while receiving che-
moradiotherapy. Biopsy of the involved tissues is
essential for the diagnosis of CMV infection and anti-
viral treatment should be instituted once the diagnosis is
established.Consent
Written informed consent was obtained from the patients
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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